Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 3/22/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Pawel Kalinski

Wrong Dr. Pawel Kalinski?

Professor of Surgery

Phone: (412) ***-****  HQ Phone
University of Pittsburgh
200 Lothrop Street
Pittsburgh, Pennsylvania 15213
United States

Company Description: The University of Pittsburgh Medical Center (UPMC) is the largest integrated health care enterprise in Pennsylvania and one of the leading nonprofit medical centers...   more
Background

Employment History

  • Professor of Bioengineering
    University of Pittsburgh
  • Professor of Surgery, Director of Research of the Division of Surgical Oncology
    UPMC
  • Director of Research, Division of Surgical Oncology
    University of Pittsburgh Cancer Institute
  • Professor of Surgery, Immunology, Bioengineering
    University of Pittsburgh Cancer Institute
  • Professor of Surgery
    University of Pittsburgh School of Medicine
  • Member, Presented Laboratory Data In Support of the Clinical Use of Combinatorial Adjuvants
    University of Pittsburgh School of Medicine

Board Memberships and Affiliations

  • Board Member
    At-Large

Education

  • MD
  • PhD
  • PhD
33 Total References
Web References
Pawel Kalinski, a professor ...
tbo.com, 22 Mar 2014 [cached]
Pawel Kalinski, a professor of surgery at the University of Pittsburgh, sees the value in that. He has done cancer immunotherapy trials, some using a patients own (autologous) tumor cells, others using tumor cells from other donors. The donated cells dont always target the cancer effectively, but the patients own cells are always a match. When we are using autologous tumor cells, we know that we will be able to treat that patient, he said.
He said StoreMyTumor might help him treat patients who are no longer candidates for surgery, or who dont have easily identifiable tumor mass.
Maybe five or 10 years from now, most of the high-risk patients tumors will be banked, one way or another, he said.
Board of Directors | Society for Immunotherapy of Cancer (SITC)
www.sitcancer.org, 27 July 2014 [cached]
Pawel Kalinski, MD, PhD (2011-2014) University of Pittsburgh Cancer Institute
Watch Hideho Okada, MD, PhD, co-leader, ...
blogs.upmcphysicianresources.com [cached]
Watch Hideho Okada, MD, PhD, co-leader, Brain Tumor Program, UPCI, and associate professor of neurological surgery, Surgery and Immunology, University of Pittsburgh School of Medicine, and Pawel Kalinski, MD, PhD, director of research, Division of Surgical Oncology, UPCI, and professor of surgery, University of Pittsburgh School of Medicine, discuss the oral presentation:
CVGT 2013 Agenda
www.ngtcancervaccines.com, 1 Oct 2013 [cached]
Pawel Kalinski, Professor of Surgery, Immunology, Bioengineering, & Inf Dis Microbiol at University of Pittsburgh Cancer Institute
In a recent presentation at the ...
news.upmcphysicianresources.com, 14 Nov 2013 [cached]
In a recent presentation at the Cancer Vaccines and Gene Therapy Meeting in Malvern, Pa., Pawel Kalinski, M.D., Ph.D., professor of surgery, University of Pittsburgh School of Medicine, presented laboratory data in support of the clinical use of "combinatorial adjuvants" that induce desirable patterns of tumor-associated inflammation and result in CTL infiltration into tumors. He also discussed preliminary data from a phase I/II trial led by Amer Zureikat, M.D., an assistant professor of surgery at Pitt, in which colorectal cancer patients were given escalating doses of interferon alpha (IFN-a) in combination with a COX2 blocker and Ampligen®, an experimental toll-like receptor-3 (TLR3) ligand, factors that synergistically enhance IFN-a's immunological effects in tumor microenvironments.
"The first part of the trial is not complete, but so far it appears that the treatment was well-tolerated," Dr. Kalinski said. "Our early observations are completely consistent with our preclinical predictions and hint that the combination therapy may be altering the tumor environment to make it more susceptible to immune attack. We are hopeful that the next, randomized part of the study will directly demonstrate the difference between the tumors of patients receiving standard treatment of chemotherapy and surgery and the patients receiving additional immunotherapy, which would lead us to expect a therapeutic benefit to this strategy."
Tumors are typically able to undermine the body's immune defenses, sending out cellular signals that call in regulatory T-cells to suppress the activity of natural killer cells, he explained. While there are many adjuvants available to enhance immune system response, most are nonselective and, therefore, ineffective. Preclinical experiments conducted by Dr. Kalinski's team indicate that the combination of IFN-a, a COX2 inhibitor and TLR3 ligands selectively brings the right kinds of immune cells to the tumor to produce what he calls "good inflammation. Such a treatment preferentially induces good inflammation within tumors, allowing the immune system to selectively attack cancer cells without inadvertently harming healthy tissues nearby.
In the second part of the study, which could begin at the beginning of next year, colorectal cancer patients will be randomly assigned to receive either conventional treatment with chemotherapy followed by surgical removal of the tumor, or to additionally receive two cycles of the IFN-a-based chemokine-modulatory regimen between chemo and surgery.
"After surgery, we will be able to compare the tumors from the two groups to see if there is a difference in their immunological microenvironment that could be beneficial," Dr. Kalinski said. "This adjuvant strategy might also work for many other kinds of cancers because it's not targeting specific tumor markers, but boosting the immune system's own ability to find cancer cells and destroy them."
He added that future efforts would aim to add a vaccine component based on dendritic cells, which recognize foreign proteins to stimulate an immune response against them.
...
tags: adjuvant agents, Amer Zureikat, cancer, cytotoxic T cells, immune responses, National Institutes of Health, Pawel Kalinski, University of Pittsburgh Cancer Institute, UPCI, UPMC, UPMC CancerCenter
Other People with the name "Kalinski":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304